For pharmaceutical executives managing drug development pipelines, toxicology directors responsible for preclinical safety assessment, and regulatory affairs professionals navigating evolving approval requirements, hERG screening has emerged as an indispensable component of cardiac safety pharmacology. The release of QYResearch’s comprehensive analysis, ”hERG Screening – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ , provides decision-makers with essential intelligence on a market experiencing rapid expansion driven by regulatory mandates and growing awareness of drug-induced cardiotoxicity risks. With the global market valued at US$ 1.186 billion in 2024 and projected to reach US$ 2.627 billion by 2031 at a compound annual growth rate (CAGR) of 12.2% , this specialized segment demonstrates the characteristics of a regulatory-driven market with expanding applications across therapeutic categories.
hERG screening refers to laboratory testing designed to assess whether drug candidates or chemical compounds interact with the human ether-à-go-go-related gene (hERG) potassium channel, scientifically designated as Kv11.1. This cardiac ion channel plays a critical role in ventricular repolarization—the process by which heart muscle cells reset electrically after each contraction. Drug-induced blockade of the hERG channel can prolong the QT interval on electrocardiograms, creating susceptibility to potentially fatal arrhythmias including torsade de pointes. Following high-profile drug withdrawals due to cardiac safety concerns, regulatory authorities worldwide now require comprehensive hERG assessment as a standard component of preclinical safety evaluation.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/4031904/herg-screening
The Regulatory Imperative: Why hERG Screening Matters
The hERG screening market’s growth trajectory is fundamentally shaped by regulatory requirements that have evolved in response to historical drug safety failures.
Regulatory history established the current framework. Several widely prescribed medications—including terfenadine (Seldane), astemizole (Hismanal), and cisapride (Propulsid)—were withdrawn from global markets following post-marketing surveillance linking them to QT prolongation and fatal arrhythmias. These events demonstrated that drug-induced hERG blockade could occur with structurally diverse compounds, creating imperative for systematic preclinical assessment.
ICH S7B guidance formalized regulatory expectations. The International Council for Harmonisation’s S7B guideline, “Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization,” established hERG assay requirements as part of integrated cardiovascular safety assessment. Regulatory authorities including FDA, EMA, and PMDA expect sponsors to characterize hERG liability before first-in-human studies, with positive findings triggering additional evaluation.
Regulatory evolution continues shaping market requirements. Updated ICH S7B implementation guidance, finalized in 2022, emphasizes integrated risk assessment combining hERG data with other preclinical information to predict clinical QT prolongation risk. This integrated approach maintains hERG screening’s central role while encouraging more sophisticated interpretation frameworks.
Technology Platforms: Evolving Assay Capabilities
The hERG screening market encompasses multiple technology platforms, each with distinct throughput, cost, and data quality characteristics.
Patch-clamp electrophysiology represents the historical gold standard, providing direct measurement of ionic current through hERG channels expressed in cultured cells. Manual patch-clamp offers highest data quality but limited throughput, suitable for detailed characterization of selected compounds. Automated patch-clamp systems—including platforms from Sophion, Nanion, and Molecular Devices—increase throughput substantially while maintaining acceptable data quality, enabling screening of larger compound libraries earlier in development.
Binding assays measure compound interaction with hERG channels using radiolabeled or fluorescent ligands. These higher-throughput methods can identify potential hERG interactors rapidly, though they do not distinguish channel blockade from other interaction modes and may generate false positives requiring follow-up electrophysiology.
Computational modeling and in silico approaches increasingly supplement experimental screening. Structure-based models predict hERG interaction potential from compound structure, enabling earlier identification of liability and guiding medicinal chemistry optimization. Machine learning algorithms trained on experimental data continue improving predictive accuracy, though regulatory acceptance of in silico data alone remains limited.
Emerging technologies including stem cell-derived cardiomyocytes and multi-electrode arrays may eventually complement or partially replace heterologous expression systems by assessing integrated cardiac electrophysiology rather than isolated channel function.
Therapeutic Applications: Beyond Antiarrhythmics
While hERG screening originated in cardiovascular drug development, its application has expanded across therapeutic categories as awareness of cardiotoxicity risk has grown.
Antiarrhythmic drug development faces inherent challenges given that many antiarrhythmics achieve therapeutic effects through ion channel modulation. For this class, hERG screening helps characterize mechanism while establishing safety margins separating therapeutic from proarrhythmic concentrations.
Antipsychotic medications have demonstrated significant hERG liability, with several agents associated with QT prolongation in clinical use. Screening enables compound selection and risk characterization for this important therapeutic class.
Antibiotics, particularly fluoroquinolones and macrolides, have shown variable hERG effects contributing to clinical QT prolongation concerns. Screening informs risk assessment and labeling for antimicrobial agents.
Oncology drugs present particular challenges given narrow therapeutic windows and patient populations with potentially compromised cardiac function. Tyrosine kinase inhibitors and other targeted therapies have shown hERG interactions requiring careful risk characterization.
Antihistamines, the class whose safety issues drove initial regulatory focus, continue requiring hERG assessment, though second-generation compounds have improved cardiac safety profiles.
Competitive Landscape: Specialized CROs and Technology Providers
The hERG screening market features specialized contract research organizations (CROs), technology providers, and pharmaceutical in-house capabilities.
Charles River Laboratories and Eurofins Scientific lead the CRO segment, offering comprehensive hERG screening services alongside broader safety pharmacology portfolios. These organizations benefit from scale, global reach, and regulatory expertise that pharmaceutical sponsors value for outsourced safety assessment.
Merck KGaA provides both services and reagents, leveraging internal expertise developed through pharmaceutical operations. This dual positioning enables technology development informed by end-user requirements.
Cyprotex Limited specializes in ADME-Tox (absorption, distribution, metabolism, excretion-toxicology) services including hERG screening, often integrated with computational modeling and data interpretation.
Specialized providers—BSYS GmbH, Creative bioarray, Metrion biosciences, Aurora Biomed—offer focused expertise in cardiac safety assessment, often combining screening services with assay development and consultation.
Technology suppliers including automated patch-clamp manufacturers enable in-house screening for pharmaceutical companies with sufficient throughput requirements to justify equipment investment.
Market Drivers: Cardiotoxicity Awareness and Pipeline Growth
Several factors beyond regulatory requirements contribute to hERG screening market expansion.
Drug development pipeline growth, particularly in oncology and specialty therapeutic areas, increases absolute demand for safety assessment services. As pharmaceutical companies advance larger numbers of candidates through preclinical development, hERG screening volumes increase correspondingly.
Earlier screening integration shifts hERG assessment from late-stage characterization toward earlier compound selection. Identifying hERG liability before significant chemistry investment reduces development costs and improves candidate quality.
Biotechnology sector growth expands the customer base for CRO-provided screening services. Smaller companies lacking in-house electrophysiology capabilities rely on external providers, creating demand that scales with sector funding levels.
Geographic expansion of pharmaceutical R&D activities into emerging markets increases global screening demand as companies establish development operations across regions.
Challenges and Limitations: False Positives and Integrated Assessment
Despite its regulatory centrality, hERG screening presents challenges requiring careful interpretation.
False positives—compounds showing hERG activity in vitro that do not cause QT prolongation in vivo—create development inefficiency. Basic hERG assay results must be interpreted considering protein binding, tissue distribution, metabolite profiles, and compensatory mechanisms that may mitigate risk in intact systems.
Integrated risk assessment frameworks combining hERG data with other preclinical information improve predictive accuracy. The comprehensive in vitro proarrhythmia assay (CiPA) initiative has advanced understanding of how multiple ion channel effects combine to determine net arrhythmia risk.
Throughput versus quality tradeoffs require strategic decisions balancing early identification of liabilities against resource constraints. Organizations must align screening strategies with pipeline characteristics and risk tolerance.
Outlook: Sustained Growth Through Regulatory Integration
The hERG screening market’s 12.2% projected CAGR through 2031 reflects sustained demand driven by regulatory requirements, expanding applications, and pharmaceutical R&D activity. For industry participants, several strategic imperatives emerge:
Regulatory alignment remains essential as guidance evolves. Service providers and technology developers must anticipate and respond to changing expectations, ensuring their offerings support regulatory submission requirements.
Integration capability differentiates providers offering comprehensive safety assessment beyond isolated hERG measurement. Combining hERG data with other cardiac safety information, computational modeling, and expert interpretation creates greater value than standalone screening.
Technology advancement continues as automated platforms improve throughput and data quality. Organizations investing in next-generation technologies gain efficiency and competitive advantage.
Global service footprint enables support for geographically distributed pharmaceutical R&D operations. Providers with multi-region capabilities capture business from global sponsors seeking consistent service quality across locations.
For pharmaceutical executives, safety assessment professionals, and investors equipped with comprehensive market intelligence—such as that provided in the QYResearch report—the hERG screening market offers sustained growth driven by fundamental requirements for cardiac safety assessment in drug development and regulatory approval processes.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
